Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib combinations as second-line treatment for metastatic gastric or gastro-oesophageal junction adenocarcinoma
2010-022793-14Phase 2Completed
- Sponsor
- AB Science
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of masitinib in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (4 arms), sponsored by AB Science. Primary endpoint: Progression-free survival. Started Nov 2010; status: completed.
02
Drugs
masitinib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2010-022793-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022793-14.